Moneycontrol PRO

you are here: HomeNewsBusinessEarningsNectar Lifesciences eyes Rs 1300cr topline in FY12

SHOW NAMES

Trending Topics

business

Nectar Lifesciences eyes Rs 1300cr topline in FY12

In an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and the road ahead.

first published: Jan 17, 2011 04:53 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live
Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347